Cargando…
Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care
Autores principales: | Barnes, Christopher J., Caon, Christina, Foley, John F., Friedman, Mark, Menzin, Joseph, Nair, Kavita V., Nichols, Christine, Olvey, Eleanor L., Owens, Gary M., Pill, Michael W., Skrepnek, Grant H., White, Leigh Ann, Zerkowski, Kristine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438258/ https://www.ncbi.nlm.nih.gov/pubmed/23383730 http://dx.doi.org/10.18553/jmcp.2013.19.s1.1 |
Ejemplares similares
-
Evidence for Long-Term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials
por: Foley, John F., et al.
Publicado: (2013) -
Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies
por: Owens, Gary M., et al.
Publicado: (2013) -
Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013) -
Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
por: Foley, John F., et al.
Publicado: (2013) -
The Changing Landscape of Hypertension and the Evolving Role of Vasodilatory Beta-Blockers
por: Bakris, George L., et al.
Publicado: (2007)